IdeS

DRUG4 trials

Sponsors

Hansa Biopharma AB

Conditions

Chronic Kidney DiseaseEnd Stage Kidney DiseaseHealthyKidney Failure, Chronic

Phase 1

Safety Study on IdeS in Healthy Volounteers

CompletedNCT01802697

Hansa Biopharma ABHealthy

Start: 2013-02-28End: 2014-02-28Updated: 2017-01-19

Phase 2

Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease

CompletedNCT02224820

Hansa Biopharma ABChronic Kidney Disease

Start: 2014-06-30End: 2015-02-28Updated: 2017-03-03

Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation

CompletedNCT02475551

Hansa Biopharma ABEnd Stage Kidney Disease

Start: 2015-06-30End: 2016-10-31Updated: 2018-01-08

A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test

CompletedNCT02790437

Hansa Biopharma ABKidney Failure, Chronic

Start: 2016-06-30End: 2018-07-03Updated: 2021-05-20

Related Papers

Five Years Follow-up of Imlifidase Desensitized Kidney Transplant Recipients.

2025-11-27

Clinical Outcomes and Donor-specific Antibody Rebound 5 y After Kidney Transplant Enabled by Imlifidase Desensitization

Transplantation Direct2025-01-093 citations

Outcomes at 3 years posttransplant in imlifidase-desensitized kidney transplant patients.

2021-07-1967 citations

IgG Degrading Enzyme of Streptococcus Pyogenes

Transplantation2017-12-239 citations

IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation

New England Journal of Medicine2017-08-02350 citations

Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS – A Novel Therapeutic Opportunity

PLoS ONE2015-07-15114 citations